{"id":"aducanumab-avwa","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT05216887","NCT05310071","NCT05469009","NCT05108922","NCT05097131"],"aliases":[],"company":"BIOGEN INC","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ADUCANUMAB-AVWA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:50:01.937594+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:50:08.237645+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ADUCANUMAB-AVWA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:50:08.623112+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Amyloid-beta A4 protein binding agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:09.697638+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3039540/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:50:09.352465+00:00"}},"allNames":"aduhelm","offLabel":[],"timeline":[],"brandName":"ADUHELM","ecosystem":[],"mechanism":{"target":"Amyloid beta A4 protein","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:10.897667+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"ADUCANUMAB-AVWA","indications":{"approved":[{"name":"Alzheimer's disease","diseaseId":"alzheimer's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"BIOGEN INC","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05216887","phase":"Phase 1","title":"A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy V","status":"COMPLETED","sponsor":"Biogen","isPivotal":false,"enrollment":123,"indication":"Healthy Volunteer","completionDate":"2022-07-27"},{"nctId":"NCT05310071","phase":"Phase 3","title":"A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease","status":"TERMINATED","sponsor":"Biogen","isPivotal":true,"enrollment":1027,"indication":"Alzheimer's Disease","completionDate":"2024-08-12"},{"nctId":"NCT05469009","phase":"EARLY/Phase 1","title":"Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients With With Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) Undergoing Stan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ali Rezai","isPivotal":false,"enrollment":15,"indication":"Mild Cognitive Impairment, Alzheimer Disease 1","completionDate":"2029-07"},{"nctId":"NCT05108922","phase":"Phase 3","title":"A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":true,"enrollment":148,"indication":"Mild Cognitive Impairment (MCI), Alzheimer Disease","completionDate":"2023-09-19"},{"nctId":"NCT05097131","phase":"N/A","title":"International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US","status":"TERMINATED","sponsor":"Biogen","isPivotal":false,"enrollment":29,"indication":"Alzheimers Disease","completionDate":"2022-05-20"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"INJECTION","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL3039540"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"BIOGEN INC","companyId":"biogen","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:50:10.897667+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}